2022年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20220924

Abstract

Abstract: 【Abstract】 Systemic lupus erythematosus has always been a research hotspot in the field of autoimmune diseases in China and other countries. In 2022, Chinese and international researchers have made a lot of new progress in epidemiology, pathogenesis, diagnosis and evaluation, and treatment of systemic lupus erythematosus. This review mainly summarizes major representative advances.

Key words: Lupus erythematosus, systemic, Diagnosis, Therapy, Incidence, Prevalence, Biological Agents, Biomarker

Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022[J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.doi:10.35541/cjd.20220924

References ［29］

［1］	Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study［J］. Ann Rheum Dis, 2023,82（3）:351⁃356. doi: 10.1136/ard⁃2022⁃223035.
［2］	Jenks SA, Cashman KS, Zumaquero E, et al. Distinct effector B cells induced by unregulated Toll⁃like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus［J］. Immunity, 2018,49（4）:725⁃739.e6. doi: 10.1016/j.immuni.2018. 08.015.
［3］	Brown GJ, Cañete PF, Wang H, et al. TLR7 gain⁃of⁃function genetic variation causes human lupus［J］. Nature, 2022,605（7909）:349⁃356. doi: 10.1038/s41586⁃022⁃04642⁃z.
［4］	Wu HJ, Ivanov II, Darce J, et al. Gut⁃residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells［J］. Immunity, 2010,32（6）:815⁃827. doi: 10.1016/j.immuni. 2010.06.001.
［5］	Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria［J］. Cell, 2009,139（3）:485⁃498. doi: 10.1016/j.cell.2009.09.033.
［6］	Flannigan KL, Denning TL. Segmented filamentous bacteria⁃induced immune responses: a balancing act between host protection and autoimmunity［J］. Immunology, 2018,154（4）:537⁃546. doi: 10.1111/imm.12950.
［7］	Valiente GR, Munir A, Hart ML, et al. Gut dysbiosis is associated with acceleration of lupus nephritis［J］. Sci Rep, 2022,12（1）:152. doi: 10.1038/s41598⁃021⁃03886⁃5.
［8］	van Drongelen V, Scavuzzi BM, Nogueira SV, et al. HLA⁃DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization［J］. Sci Rep, 2021,11（1）:2599. doi: 10.1038/s41598⁃021⁃82195⁃3.
［9］	Wang YF, Zhang Y, Lin Z, et al. Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups［J］. Nat Commun, 2021,12（1）:772. doi: 10.1038/s41467⁃021⁃21049⁃y.
［10］	Miglioranza Scavuzzi B, van Drongelen V, Kaur B, et al. The lupus susceptibility allele DRB1*03:01 encodes a disease⁃driving epitope［J］. Commun Biol, 2022,5（1）:751. doi: 10.1038/s42003⁃022⁃03717⁃x.
［11］	Pilsczek FH, Salina D, Poon KK, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus［J］. J Immunol, 2010,185（12）:7413⁃7425. doi: 10.4049/jimmunol.1000675.
［12］	Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs［J］. J Immunol, 2010,184（6）:3284⁃3297. doi: 10. 4049/jimmunol.0902199.
［13］	Monteith AJ, Miller JM, Williams JM, et al. Altered mitochondrial homeostasis during systemic lupus erythematosus impairs neutrophil extracellular trap formation rendering neutrophils ineffective at combating Staphylococcus aureus［J］. J Immunol, 2022,208（2）:454⁃463. doi: 10.4049/jimmunol.210 0752.
［14］	Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus （EUSCLE）［J］. Autoimmun Rev, 2013,12（3）:444⁃454. doi: 10.1016/j.autrev.2012.08.019.
［15］	Fernandes⁃Alnemri T, Yu JW, Datta P, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA［J］. Nature, 2009,458（7237）:509⁃513. doi: 10.1038/nature07710.
［16］	Zhao Z, Zhu H, Li Q, et al. Skin CD4+ Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus/subacute cutaneous lupus erythematosus and other skin diseases［J］. J Autoimmun, 2022,128:102811. doi: 10.1016/j.jaut.2022.102811.
［17］	Kang HM, Subramaniam M, Targ S, et al. Multiplexed droplet single⁃cell RNA⁃sequencing using natural genetic variation［J］. Nat Biotechnol, 2018,36（1）:89⁃94. doi: 10.1038/nbt.4042.
［18］	Perez RK, Gordon MG, Subramaniam M, et al. Single⁃cell RNA⁃seq reveals cell type⁃specific molecular and genetic associations to lupus［J］. Science, 2022,376（6589）:eabf1970. doi: 10.1126/science.abf1970.
［19］	Heba AC, Toupance S, Arnone D, et al. Telomeres: new players in immune⁃mediated inflammatory diseases?［J］. J Autoimmun, 2021,123:102699. doi: 10.1016/j.jaut.2021.102699.
［20］	Haque S, Rakieh C, Marriage F, et al. Shortened telomere length in patients with systemic lupus erythematosus［J］. Arthritis Rheum, 2013,65（5）:1319⁃1323. doi: 10.1002/art.37895.
［21］	Wang XF, Xu WJ, Wang FF, et al. Telomere length and development of systemic lupus erythematosus: a mendelian randomization study［J］. Arthritis Rheumatol, 2022,74（12）:1984⁃1990. doi: 10.1002/art.42304.
［22］	Apte M, McGwin G Jr, Vilá LM, et al. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort （LV）. ［corrected］［J］. Rheumatology （Oxford）, 2008,47（3）:362⁃367. doi: 10.1093/rheumatology/kem371.
［23］	Yafasova A, Fosbøl EL, Schou M, et al. Long⁃term cardiovascular outcomes in systemic lupus erythematosus［J］. J Am Coll Cardiol, 2021,77（14）:1717⁃1727. doi: 10.1016/j.jacc.2021.02.029.
［24］	Myhr KA, Zinglersen AH, Hermansen MF, et al. Left ventricular size and function in patients with systemic lupus erythematosus associate with lupus anticoagulant: an echocardiographic follow⁃up study［J］. J Autoimmun, 2022,132:102884. doi: 10.1016/j.jaut.2022.102884.
［25］	Weber BN, Stevens E, Barrett L, et al. Coronary microvascular dysfunction in systemic lupus erythematosus［J］. J Am Heart Assoc, 2021,10（13）:e018555. doi: 10.1161/JAHA.120.018555.
［26］	Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti⁃BDCA2 antibody litifilimab for systemic lupus erythematosus［J］. N Engl J Med, 2022,387（10）:894⁃904. doi: 10.1056/NEJ Moa2118025.
［27］	Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease［J］. Am J Clin Dermatol, 2022,23（6）:813⁃822. doi: 10.1007/s40257⁃022⁃00720⁃0.
［28］	Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double⁃blind, placebo⁃controlled trial［J］. Arthritis Rheumatol, 2023,75（2）:242⁃252. doi: 10.1002/art.42391.
［29］	Dunford P, Comer G, Raymond R, et al. PREVAIL 1: a multiple ascending dose study in normal healthy volunteers of PRV⁃3279, a novel bispecific DART molecule targeting CD32B and CD79B on B cells, with potential for treatment of SLE［J］. Arthritis Rheumatol, 2020,72 （suppl 10）:1701⁃1703.

[1]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 0(4): 20220819-e20220819.
[2]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[3]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[4]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[5]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220814-e20220814.
[6]	Yang Yongting, Li Tingting, Kang Xiaojing. Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2023, 56(3): 278-283.
[7]	Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220337-e20220337.
[8]	Yuan Chen, Yan Yan, Wang Baoxi . Biotherapy for acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(3): 270-273.
[9]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[10]	Ren Fenfen, Wang Peng, Zhang Jingzhan, Kang Xiaojing. Network pharmacology-based prediction of potential effective components of traditional Chinese medicine and their molecular mechanisms of action in the anti-angiogenic treatment of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220140-e20220140.
[11]	Yang Aimin, Chen Jiangwei, Huang Jiacheng, Cen Ying, Chen Junjie. Treatment of Merkel cell carcinoma [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210536-e20210536.
[12]	Yang Ji, Xu Xinzhi, Li Ming. Early diagnosis of dermatomyositis and early recognition of visceral injury [J]. Chinese Journal of Dermatology, 2023, 56(2): 161-164.
[13]	Wang Zhaoyang, Xiang Xin, Chen Yunliu, Miao Chaoyang, Zhao Xinrong, Zhang Zhenhua, Liu Yuanxiang, Ma Lin, Xu Zigang. Comparison of efficacy and safety of biologics versus methotrexate in the treatment of severe pediatric plaque psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 112-117.
[14]	Jia Yuanyuan, Mao Qiuyu, Yang Jingyi, Min Wei. Efficacy of dupilumab in the treatment of moderate and severe atopic dermatitis in the elderly: a clinical observation [J]. Chinese Journal of Dermatology, 2023, 56(2): 125-129.
[15]	Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology, The Dermatology Branch of Chinese Medical Education Association. Expert consensus on diagnosis and treatment of senile herpes zoster [J]. Chinese Journal of Dermatology, 2023, 56(2): 97-104.

Research advances in systemic lupus erythematosus in 2022

PDF

Knowledge

Abstract

Cite this article

share this article

References ［29］

Related Articles 15

Metrics

Comments

Recommended 10